Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PTEN immunohistochemical loss, a common event in endometrioid-type endometrial carcinoma and associated with local immune suppression in melanoma, was not associated with PD-L1 expression or lymphocyte/macrophage infiltration of the tumor.
|
30291344 |
2019 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
|
30569174 |
2019 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
PTEN loss in EH was significantly associated with increased risk of EC (OR = 3.32, p = 0.001).
|
30915635 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The Relationship between the Methylation of Promoter Regions of Tumor Suppressor Genes PTEN and APC with Endometrial Cancer.
|
31450893 |
2019 |
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study.
|
31348233 |
2019 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Adding PTEN/TP53 mutation testing to BHLHE22/CDO1-based methylation testing did not improve the detection of endometrial cancer.
|
31779688 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The most frequently altered gene in endometrioid endometrial carcinoma tumors is PTEN.
|
30765787 |
2019 |
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Besides, overexpression of PTEN markedly promoted the apoptosis of E2-induced RL95-2 cells through regulating the Bax and Bcl-2 expression, and modulated the expression of AKT pathway, p53 and Cyclin D. In conclusion, our findings revealed that miR-181c affected the estrogen-dependent endometrial carcinoma cell growth by targeting PTEN.
|
30971627 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine the in vitro and in vivo properties of sixteen frequently used endometrial cancer (EC) cell lines, including the cell proliferation rate, morphology, hormone receptor expression patterns, PTEN, hMLH1 expression, p53 mutation, karyotype, and tumorigenicity in mouse xenograt model.
|
30107158 |
2019 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prolactin-PRLR signaling may play a crucial role for the progression of type I EC without involving the PTEN mutation in young hyperprolactinemic women without insulin resistance.
|
29901521 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to evaluate the combination and individual expression of p53 and phosphatase and tensin homolog (PTEN) protein in human endometrial carcinoma.
|
30944646 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Furthermore, HOTAIR activated the PI3K/Akt pathway to promote EC progression by suppressing PTEN <i>in vivo</i> Taking these results together, we revealed that high expression of HOTAIR promoted cell proliferation and inhibited apoptosis through activating the PI3K/Akt pathway via binding to PTEN, which might provide a prognostic marker and therapeutic target of EC.
|
31527078 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of ABTL0812 on proliferation, cell death and modulation of intracellular signaling pathways in a wide panel of endometrioid and non-endometrioid cell lines, an inducible PTEN knock-out murine model, and two patient-derived xenograft murine models of EC.
|
30853360 |
2019 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Studies in cell cultures have demonstrated that histone deacetylase inhibitors exert their antineoplastic activity by promoting expression of p21WAF1 and p27KIP1, cyclin-dependent kinase inhibitors, that have important roles in cell cycle regulation; importantly, the transcription of specific genes (e.g., E-cadherin, PTEN) that are commonly silenced in endometrial cancer is also enhanced.
|
29509243 |
2018 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
13 EC cell lines were profiled for their PI3K pathway and KRAS mutational and PTEN protein status and treated with one MEK- and two PI3K- targeted inhibitors alone and in combination.
|
29426295 |
2018 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
It is well-known that estrogen plays an important role in the pathogenesis of endometrioid endometrial carcinoma (EEC), and induces the cancer suppressor gene PTEN deletion.
|
30584245 |
2018 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Further experiments demonstrated that the expression levels of PTEN and phosphorylated-AKT in HEC-1B and Ishikawa endometrial cancer cells was decreased and increased, respectively, following aberrant expression of miR-423. miR-423 displayed an important role in tumorigenesis and progression in endometrial cancer cells, and may therefore be used as a potential biomarker to predict chemotherapy response and prognosis in endometrial cancer.
|
30344696 |
2018 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest PI3K inhibition may be a plausible approach to expand the utility of PARP inhibitors to endometrioid endometrial cancers in a PTEN-deficient setting.
|
28945226 |
2018 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the prognostic value of the Hedgehog (Gli, Patched-1, Shh, Smo) and Notch (Jag1, Notch2, Notch3) pathway members, in comparison to a panel of proteins (ER, PgR, HER2/neu, Ki67, p53, p16, PTEN and MMR) previously suggested to be involved in the pathogenesis of endometrial cancer, in association with clinical outcome and standard clinicopathological characteristics.
|
30521558 |
2018 |
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated a high variability of individual endometrial cancer samples in the levels of PTEN.
|
29477866 |
2018 |
Endometrial Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Durable partial response was observed in a patient with endometrial cancer harboring PIK3R1 and PTEN truncating mutations, and 13 additional patients (28%) had a decrease in their target lesions by up to 30%.<b>Conclusions:</b> LY3023414 has a tolerable safety profile and single-agent activity in patients with advanced cancers.
|
29636360 |
2018 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Proliferation, transwell and apoptosis assay suggested that MDH2 enhanced the proliferation, migration and invasion but inhibited the apoptosis of endometrial cancer cell line through suppressing PTEN.
|
28189066 |
2017 |
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
miR-200a and miR-200b can promote the endometrial cancer cell growth in vitro by targeted inhibition of PTEN gene expression.
|
28647188 |
2017 |
Endometrial Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
TTF-1 and PTEN can be used as molecular markers for the early diagnosis of endometrial cancer, which are closely related to clinical features and may affect tumor progression by regulating the proliferation activity of tumor cells.
|
28745797 |
2017 |
Endometrial Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-205 was found to negatively regulate PTEN expression and lead to autophagy and activation of the AKT/mTOR pathway in PR cells, and PTEN protein levels significantly decreased with development of progesterone resistance in endometrial cancer cells.
|
28427207 |
2017 |